Showing results (371-380 of 1,188) with videos related to
Sort By:
Pageof 119
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosisSrdan Verstovsek, Ayalew Tefferi, Jorge Cortes, et al.Medicine|January 5, 2019
Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case reportSebastian Burgos, Guillermo Montalban-Bravo, Lucia Fuente, et al.International Journal of Endocrinology|December 8, 2017
Circulatory Immune Cells in Cushing Syndrome: Bystanders or Active Contributors to Atherometabolic Injury? A Study of Adhesion and Activation of Cell Surface MarkersGloria Aranda, Cristina Lopez, Rebeca Fernandez-Ruiz, et al.Cancer|December 19, 2007
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?Hagop Kantarjian, Susan O'Brien, Jianqin Shan, et al.Cancer|October 23, 2014
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemiaJean-Pierre Issa, Guillermo Garcia-Manero, Xuelin Huang, et al.Clinical Lymphoma, Myeloma & Leukemia|June 26, 2018
Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium AnalysisYazan Migdady, John Barnard, Najla Al Ali, et al.Biomed Research International|February 6, 2015
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabineTalha Badar, Jorge Cortes, Gautam Borthakur, et al.Journal of Hematology & Oncology|July 16, 2009
RIZ1 is potential CML tumor suppressor that is down-regulated during disease progressionAshakumary Lakshmikuttyamma, Naoto Takahashi, Elodie Pastural, et al.Cancer|June 25, 2005
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndromeElias Jabbour, Srdan Verstovsek, Francis Giles, et al.Clinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AMLHagop M Kantarjian, Mikkael A Sekeres, Vincent Ribrag, et al.Pageof 119